Core Viewpoint - Smurfit Westrock PLC (SW) is expected to report fourth-quarter 2025 results on February 11, with revenues projected at $7.67 billion, reflecting a 1.7% year-over-year growth, and earnings per share (EPS) estimated at 46 cents, up from 34 cents in the previous year [1][5]. Financial Estimates - The Zacks Consensus Estimate for revenues is $7.67 billion, indicating a 1.7% increase from the same quarter last year [1][5]. - The EPS consensus is set at 46 cents, showing a rise from 34 cents year-over-year [1][5]. - The earnings surprise history shows that the company has beaten the Zacks Consensus Estimate once in the last four quarters, with an average negative surprise of 18.4% [2]. Segment Performance - The Europe, MEA, and APAC segment is projected to generate revenues of $2.74 billion, up from $2.51 billion in the fourth quarter of 2024, with adjusted EBITDA estimated at $426 million, an increase from $371 million [7]. - North America's revenue estimate for Q4 2025 is $4.49 billion, slightly down from $4.52 billion reported in the previous year, with adjusted EBITDA expected to be $716 million, indicating a 0.8% year-over-year growth [8]. - The LATAM segment's revenue is estimated at $533 million, up from $505 million, but adjusted EBITDA is projected to decline to $116 million from $121 million in the prior-year quarter [9]. Market Trends and Challenges - Demand for corrugated packaging and containerboard remains stable, driven by e-commerce growth and the need for sustainable packaging solutions [3]. - However, weak volumes in Europe and lower box demand are anticipated to negatively impact quarterly results [4][5]. - Merger-related costs are expected to affect performance and free cash flow margin, although pricing actions and cost-saving initiatives may mitigate some of these challenges [6]. Stock Performance - Smurfit Westrock's stock has declined by 14.2% over the past year, compared to a 6.1% decline in the industry [11].

分组1 - Alexander's reported quarterly funds from operations (FFO) of $2.43 per share, missing the Zacks Consensus Estimate of $3.02 per share, and down from $4.06 per share a year ago, representing an FFO surprise of -19.54% [1] - The company posted revenues of $53.26 million for the quarter, missing the Zacks Consensus Estimate by 0.27%, and down from $55.91 million year-over-year, having topped consensus revenue estimates only once in the last four quarters [2] - The stock has gained about 17% since the beginning of the year, outperforming the S&P 500's gain of 1.3% [3] 分组2 - The future performance of Alexander's stock will depend on management's commentary during the earnings call and the company's FFO outlook, which includes current consensus FFO expectations for upcoming quarters [4] - The estimate revisions trend for Alexander's was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] - The current consensus FFO estimate for the upcoming quarter is $3.15 on revenues of $53.7 million, and for the current fiscal year, it is $12.52 on revenues of $216.4 million [7] 分组3 - The REIT and Equity Trust - Other industry, to which Alexander's belongs, is currently in the bottom 25% of the Zacks industry rankings, which may impact stock performance [8] - National Health Investors, another stock in the same industry, is expected to report quarterly earnings of $1.23 per share, reflecting a year-over-year change of +8.9%, with revenues expected to be $95.63 million, up 11.5% from the previous year [9][10]

Core Insights - International Flavors & Fragrances Inc. (IFF) is set to report its fourth-quarter 2025 results on February 11, with sales expected to be $2.51 billion, reflecting a 9.7% decline year-over-year [1][6] - The earnings estimate is pegged at 85 cents per share, indicating a year-over-year decrease of 12.4% [1][6] - IFF has a history of beating earnings estimates, achieving an average surprise of 9.5% over the past four quarters [3][6] Sales and Earnings Estimates - The Zacks Consensus Estimate for IFF's sales is $2.51 billion, down 9.7% from the previous year [1][6] - Earnings per share (EPS) is estimated at 85 cents, unchanged over the past 60 days [1] - The company has an Earnings ESP of +3.50%, suggesting a potential earnings beat [4] Segment Performance Projections - The Taste segment's sales are projected to decline by 0.8% year-over-year to $572 million, with adjusted operating EBITDA expected to grow by 29.3% to $113 million [10] - The Food Ingredients segment is anticipated to see a 2.7% decrease in sales to $797 million, with adjusted operating EBITDA declining by 2.7% to $98 million [10] - The Scent segment's sales are expected to decrease by 2% to $567 million, with operating EBITDA projected to rise by 1% to $107 million [11] - The Health & Biosciences segment is projected to have sales of $542 million, reflecting a 1.5% decrease, and operating EBITDA is expected to decline by 4% to $131 million [12] Cost and Margin Considerations - IFF has experienced volume growth and productivity gains, but high raw material costs and additional expenses related to labor, shipping, and cleaning are likely to have pressured margins [6][8] - Despite pricing actions and cost-reduction efforts, these factors are expected to negatively impact margins in the upcoming quarter [8] Stock Performance - Over the past year, IFF shares have decreased by 9.1%, contrasting with the industry's growth of 1.7% [13]

Core Insights - CBRE Group, Inc. is set to announce its fourth-quarter 2025 earnings on February 12, showcasing its leadership in real estate services with a comprehensive suite of offerings [2] - The company reported a 9.52% earnings surprise in the last quarter, with a year-over-year revenue growth of 14%, although the Real Estate Investments segment did not perform as well [3][4] Financial Performance - Over the past four quarters, CBRE has consistently surpassed the Zacks Consensus Estimate, with an average earnings beat of 8.5% [4] - The Zacks Consensus Estimate for quarterly revenues is projected at $11.51 billion, indicating a 10.65% year-over-year increase [8] - Advisory Services revenue is expected to reach $2.77 billion, up from nearly $2.2 billion in the prior quarter, while revenues from Building Operations & Experience are estimated at $6.32 billion, an increase from $5.79 billion [8] Market Trends and Opportunities - The company is likely to benefit from a balanced operating model with a focus on contractual revenues and increasing demand for outsourcing services [5][10] - CBRE's enterprise businesses may see support from new client acquisitions and expansions in technology, life sciences, and healthcare sectors [6] Challenges and Outlook - Despite positive trends, ongoing macroeconomic uncertainty and a competitive landscape may impact commercial real estate transaction activity [7] - Analysts have shown some pessimism regarding the company's earnings prospects, with the consensus estimate for earnings per share (EPS) decreasing by 3 cents to $2.66, although this still represents a 14.7% year-over-year increase [9]

Core Viewpoint - AppLovin (APP) shares have recently declined by 14% over the past week, but the formation of a hammer chart pattern suggests potential support and a possible trend reversal in the future [1][2]. Technical Analysis - The hammer chart pattern indicates a nearing bottom with likely subsiding selling pressure, suggesting a bullish case for the stock [2]. - A hammer pattern is characterized by a small candle body with a long lower wick, indicating that despite a downtrend, buying interest has emerged to push the stock price up towards the opening price [4][5]. - The occurrence of a hammer pattern at the bottom of a downtrend signals that bears may have lost control, indicating a potential trend reversal [5]. Fundamental Analysis - Recent upward revisions in earnings estimates for AppLovin enhance its prospects for a trend reversal, as trends in earnings estimate revisions are strongly correlated with near-term stock price movements [7]. - Over the last 30 days, the consensus EPS estimate for the current year has remained unchanged, indicating that analysts expect better earnings than previously predicted [8]. - AppLovin currently holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9][10].

Core Insights - Zacks Premium offers tools for investors to enhance their stock market strategies, including daily updates, research reports, and stock screens [1][2] Zacks Style Scores - Zacks Style Scores are indicators that help investors select stocks likely to outperform the market in the next 30 days, rated from A to F based on value, growth, and momentum [2][7] Value Score - The Value Style Score identifies attractive and discounted stocks using ratios like P/E, PEG, and Price/Sales [3] Growth Score - The Growth Style Score focuses on a company's future prospects and financial health, analyzing projected and historical earnings, sales, and cash flow [4] Momentum Score - The Momentum Style Score helps investors capitalize on price trends, using factors like one-week price changes and monthly earnings estimate changes [5] VGM Score - The VGM Score combines the three Style Scores to identify companies with the best value, growth forecasts, and momentum, serving as a strong indicator alongside the Zacks Rank [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +23.83% since 1988, significantly outperforming the S&P 500 [8][10] Stock to Watch: ATI Inc. - ATI Inc., a diversified specialty materials producer, holds a 2 (Buy) Zacks Rank and a VGM Score of A, with a Momentum Style Score of A and a 9.2% increase in shares over the past four weeks [12][13] - Four analysts have raised their earnings estimates for ATI for fiscal 2026, with the consensus estimate increasing by $0.21 to $4.12 per share and an average earnings surprise of +11.2% [13]

Company Overview - O-I Glass, Inc. is the largest manufacturer of glass containers globally, operating 69 glass manufacturing plants across 19 countries [11]. Investment Ratings - O-I Glass currently holds a Zacks Rank of 3 (Hold) and has a VGM Score of A, indicating a solid position in the market [11]. Momentum and Performance - The company has a Momentum Style Score of A, with shares increasing by 7.4% over the past four weeks [12]. - An analyst has revised their earnings estimate higher for fiscal 2025, with the Zacks Consensus Estimate increasing by $0.01 to $1.60 per share [12]. - O-I Glass has demonstrated an average earnings surprise of +53.8%, suggesting strong performance relative to expectations [12].

Core Insights - Zacks Premium offers various tools for investors to enhance their stock market strategies and confidence [1] - The Zacks Style Scores are designed to help investors identify stocks with the potential to outperform the market in the short term [2] Zacks Style Scores Overview - The Style Scores consist of four categories: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6] Value Score - The Value Style Score identifies stocks that are undervalued based on financial ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow [3] Growth Score - The Growth Style Score assesses a company's financial health and future growth potential by analyzing projected and historical earnings, sales, and cash flow [4] Momentum Score - The Momentum Style Score focuses on stocks with upward or downward price trends, utilizing factors like one-week price changes and monthly earnings estimate changes [5] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors who utilize multiple investment strategies [6] Zacks Rank Integration - The Zacks Rank is a proprietary model that uses earnings estimate revisions to help investors build successful portfolios, with 1 (Strong Buy) stocks achieving an average annual return of +23.83% since 1988 [7] - There are typically over 800 top-rated stocks available, making it essential to use Style Scores to narrow down choices [8] Investment Strategy - For optimal returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [9] - Stocks with lower ranks but high Style Scores may still face downward price trends due to negative earnings forecasts [10] Company Spotlight: Evercore (EVR) - Evercore Inc. is a leading independent investment banking advisory firm with a Zacks Rank of 3 (Hold) and a VGM Score of B [11] - The company is projected to have a year-over-year earnings growth of 27.2% for the current fiscal year, with upward revisions in earnings estimates [12] - Evercore's average earnings surprise stands at +50.9%, making it a strong candidate for growth investors [12]

Company Overview - Corpay, Inc. is a global commercial payments solution provider based in Peachtree Corners, GA, helping companies automate, secure, digitize, and control payments for employees and suppliers [11] - The company serves businesses, partners, and merchants across North America, Latin America, Europe, and the Asia Pacific [11] Investment Ratings - Corpay has a Zacks Rank of 3 (Hold) and a VGM Score of B, indicating a moderate investment outlook [11] - The Value Style Score for Corpay is also rated B, supported by a forward P/E ratio of 14.04, which is attractive for value investors [12] Earnings Estimates - In the last 60 days, three analysts have revised their earnings estimates higher for fiscal 2026, with the Zacks Consensus Estimate increasing by $0.40 to $25.22 per share [12] - Corpay has an average earnings surprise of +0.8%, suggesting a positive trend in earnings performance [12] Investment Considerations - With a solid Zacks Rank and strong Value and VGM Style Scores, Corpay is recommended for investors' consideration [12]

Company Overview - ALX Oncology Holdings Inc. (ALXO) is part of the Medical sector, which includes 928 individual stocks and holds a Zacks Sector Rank of 10 [2] - ALX Oncology is currently rated with a Zacks Rank of 2 (Buy), indicating a positive earnings outlook [3] Performance Metrics - Over the past three months, the Zacks Consensus Estimate for ALXO's full-year earnings has increased by 16.9%, reflecting improved analyst sentiment [4] - ALXO has returned approximately 81.4% year-to-date, significantly outperforming the average gain of 5.3% for Medical stocks [4] - In the Medical - Biomedical and Genetics industry, which includes 449 companies, ALXO is performing better than the average industry gain of 23.6% this year [6] Comparative Analysis - Another Medical stock, Amneal Pharmaceuticals (AMRX), has returned 15.2% year-to-date and has a Zacks Rank of 2 (Buy) [5] - Amneal Pharmaceuticals belongs to the Medical - Drugs industry, which has a lower year-to-date gain of +2.7% and is ranked 146 [7]